Navigation Links
New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits

- Bifantis shows ability to limit inflammation in models of arthritis and Salmonella infection, according to data presented at Digestive Disease Week -

WASHINGTON, May 21, 2007 /PRNewswire/ -- The biotechnology company Alimentary Health today announced results from two studies that demonstrate the anti-inflammatory activity of a natural probiotic bacterial strain of human origin, Bifantis(R) (Bifidobacterium infantis 35624), in models of arthritis and Salmonella infection. Data from these studies were presented this week at the 38th annual Digestive Disease Week (DDW) conference taking place in Washington D.C.

The inflammatory response is a key part of the immune system's battle against invaders, but in certain conditions and diseases, it can do more harm than good by injuring healthy tissue. Inflammation is associated with a variety of conditions, such as inflammatory bowel disease, arthritis, cardiovascular disease, diabetes, Alzheimer's disease and more. Bifantis has previously been shown to modulate the inflammatory response in a clinical trial in irritable bowel syndrome. The results announced this week demonstrate that the anti-inflammatory effects of Bifantis are not restricted to the gastrointestinal tract.

"Inflammation is a major factor in a number of chronic diseases, which affect millions of people," said Barry Kiely, Chief Executive Officer, Alimentary Health and an early investigator of the probiotic effects of Bifantis. "Data continue to show that Bifantis has anti-inflammatory activity, which may be useful in the management of inflammation-linked diseases."

In one of the studies released today, four bacterial strains were fed to mice. Of these four strains, researchers determined that only Bifantis delayed the onset of artificially induced arthritis and resulted in less severe arthritic symptoms. This study represents some of the latest work assessing the link between diet i nvolving probiotics and certain autoimmune diseases.

In the second study, mice were fed Bifantis and then exposed to Salmonella, a common bacteria associated with a form of food poisoning. Animals that received Bifantis showed dramatically increased numbers of certain immune cells that control the immune system's response to harmful pathogens, in this case Salmonella. Bifantis also increased the numbers of T- regulatory cells in the body, in effect limiting the concentrations of certain signals essential to inflammation, such as cytokines.

About Alimentary Health

Alimentary Health is a development stage specialty biotechnology company linked to the Alimentary Pharmabiotic Centre based at University College Cork, Cork, Ireland. Alimentary Health is focused on the discovery, development and commercialization of proprietary treatments for gastrointestinal disorders and other inflammatory conditions.

About APC

The Alimentary Pharmabiotic Centre (APC) is a Science Foundation Ireland (SFI) funded research centre headquartered in University College Cork (UCC), with scientists and clinicians also based in Teagasc Moorepark, Cork University Hospital and Alimentary Health Ltd. The APC is investigating mechanisms by which intestinal bacteria influence health and disease and is developing new therapies for lifelong debilitating gastrointestinal diseases such as gastroenteritis, ulcerative colitis and Crohn's disease. For information please visit http://apc.ucc.ie/.

CONTACT: Barry Kiely, of Alimentary Health, +353-86-8099162,; Adriane Hirsch-Klein, of Manning, Selvage & Lee forAlimentary Health, +1-212-468-4122, BKiely@ahealth.ie Adriane.Hirsch-Klein@mslpr.com

Web site: http://apc.ucc.ie/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
2. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
3. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
7. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year.  Reported sales decreased 3% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... Adjusted EPS was $4.65, an increase of 10% over ...
Breaking Medicine Technology:
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... speaking on how healthcare companies can use newly released government data on populations ... a population and intervene and capture the value they create to succeed in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... Texas (PRWEB) , ... February 07, 2016 , ... ... new MyDecision™ program. MyDecision™ empowers employers and organizations with the tools and information ... MyDecision™ combines three elements to cut the cost of providing employee healthcare benefits ...
(Date:2/6/2016)... CA (PRWEB) , ... February 06, 2016 , ... US ... Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ultimate organizations, ... Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of Youth and ...
Breaking Medicine News(10 mins):